James R. Sulat

James R. Sulat discloses dealings in 7 companies, chiefly AMAG Pharmaceuticals Inc., Momenta Pharmaceuticals Inc and Arch Therapeutics, Inc. In total, 42 filings cover trades dated from 5 June 2006 to 14 November 2023.

Every open-market trade on record is a purchase: 5 purchases worth €328k, and no sale. No amount is published for 1 filing, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 16 share grants and 10 option exercises. In 2023 alone, the filings show 2 purchases and no sales.

Half of the purchases are above €98k and half below.

The latest filing, published on 16 November 2023, reports a transaction in Mallinckrodt plc. The clock since the last published purchase (16 March 2023) now reads 1,318 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.